Carisoprodol (Soma) for Severe Muscle Spasms After a Car Accident

James Wong — Founder & Pharmacist, LienScripts | September 14, 2024 | 6 min read

Carisoprodol (Soma) is a centrally-acting muscle relaxant prescribed for severe acute muscle spasms following injury. It is more potent than commonly used alternatives, carries scheduling concerns, and requires careful prescribing — but for appropriate patients with significant spasm, it may be the right clinical choice.

[!KEY] Carisoprodol (Soma) is a Schedule IV muscle relaxant reserved for severe acute spasm that has not responded to first-line agents like cyclobenzaprine or methocarbamol — its prescription documents that the treating physician found initial therapy inadequate and the spasm severe enough to warrant a more potent, more regulated agent, typically for a short 2-3 week acute course.

What Is Carisoprodol?

Carisoprodol (brand name Soma) is a Schedule IV controlled substance and centrally-acting skeletal muscle relaxant. It is prescribed for acute musculoskeletal pain and spasm, typically in short courses of 2-3 weeks. It is more potent than the muscle relaxants more commonly prescribed in personal injury settings (cyclobenzaprine, methocarbamol, tizanidine) and is generally reserved for severe spasm that hasn't responded adequately to those agents.

Carisoprodol works through its active metabolite, meprobamate — itself a controlled substance — which has sedative, anxiolytic, and muscle-relaxant properties. The pharmacology is distinct from other muscle relaxants, and the abuse potential is higher than alternatives, which is why its use is reserved for cases with genuine clinical need.

Why Physicians Prescribe Soma After Accidents

After a severe motor vehicle accident — especially one involving a significant impact to the cervical or lumbar spine — muscle spasm can be intense enough to be disabling. Cervical spasm that prevents range of motion, lumbar spasm that makes it impossible to sit or stand for more than a few minutes, and thoracic spasm following chest or rib injuries can require more aggressive pharmacological management than first-line muscle relaxants provide.

Physicians prescribe carisoprodol when:

• First-line muscle relaxants (cyclobenzaprine, methocarbamol) have not provided adequate relief
• The spasm is severe enough to interfere with basic function — mobility, sleep, PT participation
• The clinical picture warrants the more potent agent, and the prescribing physician has assessed the risk-benefit appropriately
• The intended course is short (typically 2-3 weeks)

Because of the scheduling and dependency concerns, carisoprodol prescribing requires clinical judgment and is typically not the first muscle relaxant prescribed. It is reserved for cases with genuine, documented severe spasm.

Legal Significance in PI Cases

[!TIP] The strongest defense against challenges to a carisoprodol prescription is prior clinical records showing that less potent muscle relaxants were tried and found inadequate — document the medication arc from cyclobenzaprine through Soma to establish the escalating severity of the spasm-producing injury.

Carisoprodol is a more potent and more regulated muscle relaxant than the alternatives. When a treating physician prescribes it, the clinical signal is that the patient's spasm was severe enough to require a Schedule IV agent. For PI cases involving significant soft tissue or musculoskeletal injury, this prescription creates documentation that the injury severity warranted aggressive pharmacological management.

Defense counsel may attempt to use a carisoprodol prescription against the patient — arguing that the patient was being over-prescribed or that the prescribing was inappropriate. The counter-argument is straightforward: a licensed physician with prescribing authority assessed the patient's clinical presentation and determined that this medication was medically necessary. The physician's clinical judgment is documented in the prescribing record.

For PI attorneys, a carisoprodol prescription in the medication record is most defensible when the clinical records show:

• Prior treatment with less potent muscle relaxants that were inadequate
• Documented severe spasm on physical examination
• A short prescribed course consistent with acute treatment guidelines

Short Course Treatment

Carisoprodol should generally be prescribed for no more than 2-3 weeks. This is consistent with FDA labeling and clinical guidelines. For PI patients, this means carisoprodol is typically a short-course treatment in the acute phase, transitioning to alternatives (cyclobenzaprine, tizanidine) for ongoing muscle relaxant needs if required.

A patient prescribed carisoprodol for 2 weeks followed by a transition to cyclobenzaprine for ongoing spasm management shows a logical, clinically coherent medication arc that is consistent with appropriate prescribing practices.

[!KEY] A carisoprodol prescription is most defensible when the clinical record shows it followed failed first-line muscle relaxants — the prescribing arc from cyclobenzaprine to Soma is itself evidence of escalating injury severity and supports a higher damages evaluation for the overall soft tissue claim.

Coverage Under a Pharmacy Lien

Carisoprodol prescribed for acute, severe injury-related muscle spasm is covered under a LienScripts pharmacy lien for eligible PI cases. Because it is a Schedule IV controlled substance, dispensing requires a prescription with the appropriate regulatory documentation.

[!KEY] When carisoprodol is dispensed through a pharmacy lien program, the pharmacist review process evaluates for CNS depressant combination risks — attorneys should ensure their clients understand that all current medications, including opioids and benzodiazepines, must be disclosed to prevent dangerous interactions.

The LienScripts pharmacist review process evaluates all controlled substance prescriptions for clinical appropriateness and drug interaction risks. Carisoprodol combined with opioids, benzodiazepines, or other CNS depressants carries an enhanced sedation risk, and the reviewing pharmacist will flag significant combination risks.

Patients prescribed carisoprodol as part of their injury treatment who are having difficulty accessing the medication should ask their attorney about pharmacy lien options. For more information, visit for patients.

Related Resources

• Pharmacy Services for Personal Injury Clients: How It Works
• Cyclobenzaprine for Personal Injury Cases: What Attorneys Need to Know
• What Are Medication Liens?